Pfizer Anticipates Prevnar 13 For Older Adults Will Get Advisory Review In September
This article was originally published in The Pink Sheet Daily
Executive Summary
After the advisory committee, FDA would have one month to complete its review before the next ACIP meeting.
You may also be interested in...
Prevnar 13 Advisory Committee Review Moved Back To November
Revised schedule allows FDA to evaluate additional data on concomitant use of Pfizer's pneumococcal disease vaccine with flu vaccine for older adults, but could cause extra delays at CDC.
Prevnar 13 Advisory Committee Review Moved Back To November
Revised schedule allows FDA to evaluate additional data on concomitant use of Pfizer's pneumococcal disease vaccine with flu vaccine for older adults, but could cause extra delays at CDC.
Pediatric Meningococcal Vaccine's Approval Pathway May Work For Other Disease Areas
FDA suggests serum bactericidal antibody measurements to predict protection from meningococcal diseases in children under age 2.